Evidence map›Paper›PMID 37840829›Full record

ArticleInfection and drug resistance2023

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory

Kazuki Hashimoto, Takuro Nii, Hitoshi Sumitani, Masashi Yokoyama, Satoshi Miyamoto, Yasuhiro Mihashi, Yuka Nagata, Takanori Matsuki, Kazuyuki Tsujino, Keisuke Miki and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kazuki HashimotoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Takuro NiiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Hitoshi SumitaniDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Masashi YokoyamaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Satoshi MiyamotoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Yasuhiro MihashiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Yuka NagataDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Takanori MatsukiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Kazuyuki TsujinoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Keisuke MikiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.ORCID 0000-0002-3600-8595
Hiroshi KidaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.ORCID 0000-0002-9351-7855
Toneyama National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amikacin liposome inhalation suspension (ALIS) is a key drug for the treatment of refractory

Indexed as

amikacin liposome inhalation suspensiondrug-induced interstitial lung diseasedrug provocation testMycobacterium avium complex pulmonary diseaseparadoxical response

Identifiers

PMID37840829
PMCPMC10576464
OpenAlexW4387499316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.